Evidence map›Paper›PMID 40699929›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

A multifunctional anti-O-Antigen human monoclonal antibody protects against

Matteo Ridelfi, Giacomo Vezzani, Emanuele Roscioli, Giampiero Batani, Elena Boero, Francesco Nannini, Eleonora Marini, Ushasi Bhaumik, Girmay Desalegn, Ornella Serpino and 32 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Matteo Ridelfi *Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Giacomo Vezzani *GSK Vaccines Institute for Global Health, Siena 53100, Italy.
Emanuele Roscioli *Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Giampiero Batani *Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Elena Boero *GSK Vaccines Institute for Global Health, Siena 53100, Italy.
Francesco NanniniMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Eleonora MariniMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Ushasi BhaumikDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.
Girmay DesalegnDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.
Ornella SerpinoDipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II, Napoli 80138, Italy.
Antonio MolinaroDipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II, Napoli 80138, Italy.
Ida PacielloMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Chiara MugnainiMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Concetta De SantiMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Giuseppe MaccariData Science for Health Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Antonella De RosaFondazione Toscana Life Sciences, Siena 53100, Italy.
Silvia ValensinFondazione Toscana Life Sciences, Siena 53100, Italy.
Assia DuattiGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Roberta Di BenedettoGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Maria Michelina RasoGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Renzo AlfiniGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Chiara SammicheliGlaxoSmithKline, Siena 53100, Italy.
Simona TavariniGlaxoSmithKline, Siena 53100, Italy.
Christina QuigleyDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229.
Audino PoddaGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Anna KabanovaMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Emanuele AndreanoMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Dario CardamoneData Science for Health Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Gianmarco GasperiniGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Francesca NecchiGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Mariagrazia PizzaGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Laura B MartinGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Robert W FrenckDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229.ORCID 0000-0002-2336-526X
Alexandre GrassartInstitut Pasteur de Lille, Lille 59000, France.
Alba SilipoDipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II, Napoli 80138, Italy.ORCID 0000-0002-5394-6532
Marcela F PasettiDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.
Francesco Berlanda ScorzaGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Carlo GiannelliGSK Vaccines Institute for Global Health, Siena 53100, Italy.ORCID 0000-0002-6112-6841
Omar RossiGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Francesca MicoliGSK Vaccines Institute for Global Health, Siena 53100, Italy.
Claudia SalaMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Rino RappuoliFondazione Biotecnopolo di Siena, Siena 53100, Italy.ORCID 0000-0002-8827-254X

Funding

Wellcome TrustWellcome Trust (WT) 219666/Z/19/Z
6 · The paper itself

Abstract

Shigellosis is a global public health challenge that mostly affects low- and middle-income countries and causes considerable morbidity and mortality among children under 5 y of age. Multi- and extensively drug-resistant

Indexed as

Antibodies, BacterialAntibodies, MonoclonalDysentery, BacillaryO AntigensShigella sonneiAnimalsFemaleHumansMiceMice, Inbred BALB CShigella VaccinesAntibodies, BacterialAntibodies, MonoclonalO AntigensShigella Vaccinesantimicrobial resistancehuman monoclonal antibodiesO-AntigenShigella sonneishigellosis

Identifiers

PMID40699929
PMCPMC12318208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.